Six-center national consortium to study changes in human immune system
Ellis Reinherz, MD
The National Institute of Allergy and Infectious Diseases (NIAID) has
awarded a group of researchers at Dana-Farber Cancer Institute a $6.5
million, five-year grant to fund research focused on developing a
universal vaccine against human influenza A viruses.
Ellis L. Reinherz, MD,
faculty director of the Cancer Vaccine Center at Dana-Farber and a
professor of medicine at Harvard Medical School, is the principal
investigator for the Dana-Farber grant. The other Dana-Farber
collaborators include Vladimir Brusic, PhD, Bruce Reinhold, PhD,
Jonathan Duke-Cohan, PhD, Derin Keskin, PhD, and Guanglan Zhang, PhD.
"This grant will enable us to investigate a new approach in an effort
to develop a T cell-based vaccine against human influenza A viruses,"
"Our ultimate goal is a vaccine that targets the conserved viral
segments that cannot vary from one viral strain to another, thereby
providing protection against all seasonal and pandemic flus. Such an
advance will eliminate the need to alter the vaccine when there is a new
global threat, as is necessary for current antibody-inducing
The grant is part of the NIAID's newly launched nationwide research
initiative to define changes in the human immune system in response to
infection or to vaccination.
Dana-Farber is one of six U.S.-based Human Immune Phenotyping Centers
that collectively will receive a total of $100 million over five years
to conduct this research.
The other centers are Baylor Research Institute, Dallas; Emory
University, Atlanta; Mayo Clinic, Rochester, Minn.; Stanford University,
Calif.; and Yale University, New Haven, Conn. Support for the first
year of this initiative will come from the American Recovery and